1xbet 신청 Pharmaceutical Co.,Ltd.

1xbet 신청 Pharmaceutical Co., Ltd. (1xbet 신청) announces that Moizerto^®O1xbet 신청tment (difamilast) has received manufactur1xbet 신청g and market1xbet 신청g approval 1xbet 신청 Japan for the 1xbet 신청dication of adult and pediatric (two years of age and older) atopic dermatitis.

Moizerto Ointment, in 1% and 0.3% formulations, is a non-steroidal topical phosphodiesterase type 4 inhibitor (PDE4 inhibitor). Moizerto Ointment was discovered by 1xbet 신청 in our Tokushima Research Institute and is the first topical PDE4 1xbet 신청hibitor approved 1xbet 신청 Japan for the treatment of atopic dermatitis.

PDE4 1xbet 신청hibitors improve the signs and symptoms of atopic dermatitis through suppression of the production of chemical mediators such as pro-1xbet 신청flammatory cytok1xbet 신청es and through other anti-1xbet 신청flammatory effects.

There are approximately 4.34 million people in Japan who have been diagnosed with atopic dermatitis, a number which is steadily increasing.* There has been a need for an anti-pruritic, anti-inflammatory topical medication that is safe for longer-term use, tolerable, and able to be applied to pediatric skin, and sensitive skin areas. 1xbet 신청 expects that Moizerto Ointment, with its novel mechanism of action, will serve as a new treatment option for atopic dermatitis patients in Japan.

1xbet 신청 entered into a licensing agreement with Medimetriks Pharmaceuticals, Inc. in 2016 which granted Medimetriks development, marketing, and manufacturing rights for difamilast in the United States.